Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Oral heart failure drug receives FDA’s fast track designation
A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.
$64M raised for new cardiogenic shock drug—research already underway
Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.
‘Unprecedented’: Single dose of new gene-editing therapy lowers cholesterol, triglycerides
First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.

stroke brain dementia alzheimer's puzzle mental health

Stroke after TAVR in AFib patients: Key risk factors cardiologists should know

Reviewing a patient's medical history can help care teams select the optimal post-TAVR oral anticoagulation strategy.

doctor examines patient data on their tablet

New CVD risk calculator could end statin therapy eligibility for millions of heart patients

The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

Some weight loss patients are overdosing on semaglutide, FDA warns

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications.

healthcare value value-based care money dollar

Cardiology Funding Roundup: Cardurion, Kestra, TRiCares all secure key investments

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another.

Pharmacists help lower stroke risk in patients with undiagnosed, undertreated AFib

Researchers described pharmacies as an “attractive setting for community-based AFib screening."

PHOTO GALLERY: AMA display of medical quackery and ineffective, dangerous alternative medicine

The American Medical Association has a collection of artifacts on health fraud quackery at its Chicago headquarters office.

weight loss scale overweight obese lose weight pounds

Diabetes drug tirzepatide linked to more significant weight loss than semaglutide

Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

Blood pressure drug could make leukemia more responsive to chemotherapy

“This finding shows great potential to enhance the success of chemotherapy while protecting the heart," one researcher said.

Pharmaceutics

Beta-blockers do not benefit heart attack patients with a normal LVEF

Oral heart failure drug receives FDA’s fast track designation

Winning cash for taking blood pressure meds increases compliance

$64M raised for new cardiogenic shock drug—research already underway

‘Unprecedented’: Single dose of new gene-editing therapy lowers cholesterol, triglycerides